# Progress Note 04 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ray Charles (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML009-SYN
- Date: 2026-09-01
- Fictional facility: St. Posthumous Health Center
- Fictional author: Gloria Fenwick, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month review with depression screening and the plan for any future pain. **S**

## History of present illness

Mr. Charles returns six months after his first visit. He has had no opioid or other drug use and no cravings. His mood is good, and he answered the PHQ-9 aloud today with a score of 2, with no thoughts of suicide or self-harm. His eyes have been comfortable. He has had no falls. The naloxone sprays are in date. He finished the written plan for any future pain with Dr. Fenwick today and has it saved on his phone. **S**

| Element | Detail |
|---|---|
| Recovery | Sustained remission; no cravings |
| Mood | PHQ-9 2; item 9 scored 0 |
| Pain plan | Finished and saved on his phone |
| Falls | None in six months |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Eyes | Negative | No eye pain, redness, or discharge |
| Psychiatric | Negative | Mood good; no cravings; no thoughts of suicide or self-harm; PHQ-9 score 2 |
| Musculoskeletal | Negative | No falls or pain |

3 systems reviewed. **S**

## Current medications

- Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/76 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 80 kg; BMI 25.2 kg/m². All vital signs are synthetic.

PHQ-9: 2. All results are synthetic.

## Change since baseline

- PHQ-9: 2 at baseline, 2 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert, warm, and engaged |
| Eyes | No light perception; lids and ocular surfaces quiet |
| Psychiatric | Euthymic; organized thought; no signs of intoxication or withdrawal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Opioid use disorder, in sustained remission** (F11.21). Sustained remission continues. PHQ-9 2, with no thoughts of suicide. The plan for any future pain is complete: non-opioid treatment first; if an opioid is ever needed after surgery or an injury, the smallest supply for the shortest time from one prescriber, with a support person told, naloxone at hand, and a follow-up visit within a week. **S**
   - Keep the pain plan on his phone and share it with any surgeon or emergency team.
   - Continue the recovery check at each visit.
2. **Blindness of both eyes since childhood** (H54.0X55). Eyes comfortable and quiet. **S**
   - Yearly ophthalmology review in the spring.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Eye comfort and ocular surface check: pain, redness, discharge | Every visit | Completed today | No pain, redness, or discharge |
| Examination | Tonometry (eye pressure) | Every glaucoma visit; for blind eyes, only if pain or redness | Not indicated | Painless blind eyes, as advised by ophthalmology |
| Examination | Comprehensive eye examination | Yearly for blind eyes, or with symptoms | Up to date | Ophthalmology examination five months ago; next in the spring |
| Survey | Depression screen (PHQ-9) | At intake, at six months, and yearly | Completed today | PHQ-9 2, read aloud, with item 9 scored 0 |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline still saved in his phone |
| Self-management | Recovery check: any return to use, cravings, triggers, and supports | Every visit | Completed today | No return to use and no cravings |
| Medication safety | Naloxone at home and when traveling | At intake; check expiry at each visit | Completed today | Both sprays in date |
| Survey | Drug-use screen (DAST-10) | Yearly | Up to date | DAST-10 0 six months ago; next at the annual wellness visit |
| Survey | Alcohol screen (AUDIT-C) | Yearly | Up to date | AUDIT-C 2 six months ago; next at the annual wellness visit |
| Laboratory | Hepatitis C, hepatitis B, and HIV testing | At entry to care for a person with a substance use disorder | Due | At the annual wellness visit next month |
| Self-management | Written plan for any future acute pain or surgery | Before any planned procedure, and once in remission | Completed today | Finished today and saved in an accessible format on his phone |
| Self-management | Accessible documents and communication | Every visit | Completed today | Pain plan and visit summary sent as accessible documents |
| Medication safety | Medicine labeling in braille or audio | With every new prescription | Up to date | No new prescriptions |
| Examination | CDC STEADI fall-risk screen | Every visit from age 65 | Completed today | No falls in six months |
| Self-management | Advance care planning | Yearly from age 65 | Due | At the annual wellness visit next month |
| Self-management | Vaccinations | Yearly, per the CDC schedule | Due | Influenza and pneumococcal vaccines at the annual wellness visit next month |

## Goal progress

- Visit summaries, results, and medicine information delivered in an accessible electronic format, and medicine labels in braille or audio, by the four-week visit. Outcome by 2026-03-31: Visit summaries sent as accessible documents; the pharmacy provides audio labels and a braille label on the naloxone. **S**
- Naloxone at home and in his travel bag, with a tactile label, and the people he travels with shown how to use it, by the three-month visit. Outcome by 2026-06-02: Naloxone in both places; travel staff shown how to use it. **S**
- Stay in sustained remission, with no return to opioid use, through six months. Outcome by 2026-09-01: No opioid use; DAST-10 0 at intake and no use reported at each visit. **S**
- No falls through six months. Outcome by 2026-09-01: No falls. **S**
- A written plan for any future acute pain or surgery that uses non-opioid treatment first and builds in safeguards if an opioid is ever needed, by the six-month visit. Outcome by 2026-09-01: Plan written with him and saved in an accessible format. **S**

## Guideline basis

- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- Primary Open-Angle Glaucoma Preferred Practice Pattern (2025), American Academy of Ophthalmology
- Vision Rehabilitation Preferred Practice Pattern (2023), American Academy of Ophthalmology (Ophthalmology)
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, glaucoma and depression, bipolar, and mood disorders monographs (2026), Aether Forge

## Follow-up

- Annual wellness visit in five weeks, with the hepatitis and HIV tests, vaccines, and advance care planning. **S**
- Next scheduled visit 2026-10-06: subsequent annual wellness visit. **S**
